Abstract
The aim of this work was to develop a method of RP HPLC for the quantitative determination of aminocaproic acid in a complex nasal drug.Materials and methods. A solution of aminocaproic acid and a solution of a complex model mixture containing aminocaproic acid were used for the study purposes. A method used for sample preparation was derivatization of aminocaproic acid with dansyl chloride. A method of quantitative determination was RP HPLC analysis with UV detection at 288 nm.Results. The obtained data confirm the specificity, linearity, and correctness of the method proposed for quantitative analysis. Therewith, the correlation coefficient, limit of detection, limit of quantification and relative standard deviation (RSD) are R=0.9998, LOD=4.6·10-5 g/mL, LOQ=1.4·10-4 g/mL, and RSD=1.16% respectively.Conclusions. A method of RP HPLC for the quantitative determination of aminocaproic acid in a complex nasal drug has been developed and its validation assessment has been carried out according to the following validation parameters: specificity, accuracy, linearity, and precision (repeatability). Statistical processing of the obtained results shows that all the validation parameters studied are within the acceptance criteria
Highlights
Influenza and acute respiratory viral infections (ARVIs) are among the most common viral diseases with up to incidents rate 0.07–0.13/10,000 population in epidemic season [1,2,3], as it was found in following economically developed countries: Australia [4], USA [5], Canada [6, 7], Great Britain [8], Europe [9]
Aminocaproic acid has a number of important pharmacological activities: hemostatic, detoxifying, capillary strengthening, anti-allergic, and it inhibits a number of enzymes and exhibits antiviral activity against influenza virus [14, 15]
In the first part of the studies, we investigated the specificity of the method suggested, which involved using the reaction of dansyl chloride with aminocaproic acid in a separate solution and in the model mixture of active substances
Summary
Influenza and acute respiratory viral infections (ARVIs) are among the most common viral diseases with up to incidents rate 0.07–0.13/10,000 population in epidemic season [1,2,3], as it was found in following economically developed countries: Australia [4], USA [5], Canada [6, 7], Great Britain [8], Europe [9]. Aminocaproic acid has a number of important pharmacological activities: hemostatic, detoxifying, capillary strengthening, anti-allergic, and it inhibits a number of enzymes and exhibits antiviral activity against influenza virus [14, 15]. In previous in vitro studies of anti-influenza activity, a synergistic effect of ACA and PABA mixture (at component ratio of 100:1) and high index of selectivity were determined [17, 18]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
